Alethio Therapeutics

Series-A
alethiomics.com Biotech & Healthcare Abingdon-on-thames
Total Funding $90M
Latest Round $90M Series-A
Last Announced Nov 5, 2026
Investors 5 Backers
Decision Makers 6 Available

About Alethio Therapeutics

Alethiomics is a biotech company harnessing the power of single-cell multi-omic technology to discover & develop treatment for blood cancer.

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-A
Global Headquarters Abingdon-on-thames
Tracked Since Nov 5, 2026

Web & Domain Identity

Official Website alethiomics.com
Domain Registered Date Undisclosed

Social & Network Presence

X / Twitter Profile @companies
LinkedIn Corporate Company Profile

Company Milestones & Timeline

1 Events
  1. Capital Raise

    Raised $90,000,000 · Series-A

    Backed by RA Capital Management

Investors & Backers

5
RA Capital Management
Lead
Cancer Research Horizons
Oxford Science Enterprises
Sofinnova Partners
University of Oxford

Funding History

1 Round
Series-A equity · Nov 5, 2026

Round backers: RA Capital Management

Founders & Leadership

3

Adam Mead

Founder

Work email & phone locked Unlock →

Bethan Psaila

Founder

Work email & phone locked Unlock →

Edward Ainscow

Chief Scientific Officer

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

Recently funded startups
New SaaS launches
Never pay twice for contacts